Senior Vice President, Regulatory and Quality · LEXICON PHARMACEUTICALS, INC. (LXRX)

Kenneth Kassler-Taub

A named executive officer of LEXICON PHARMACEUTICALS in every fiscal year CompBrief holds from FY2020 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$1,476,975

Salary $424,148Stock awards $264,544Bonus $151,778

FY2021: $942,599

4th of 5 named executive officers at Lexicon Pharmaceuticals by FY2022 total.

5 named officers on file for LEXICON PHARMACEUTICALS, FY2022

Kenneth Kassler-Taub’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • LXRX’s disclosed peer group of 22 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how LEXICON PHARMACEUTICALS’s whole pay program stands against its peers

  • LEXICON PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on LXRX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 17, 2023 (DEF 14A).

Free

Get Kenneth Kassler-Taub’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Kenneth Kassler-Taub compensation by year

LEXICON PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held
In US dollars, as LEXICON PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022
Salary$375,060$392,646$424,148
Bonus$116,196$152,807$151,778
Stock awards$181,156$178,159$264,544
Option awards$201,309$206,860$623,733
Non-equity incentive$0$0$0
Pension and deferred compensation$0$0$0
All other$12,018$12,127$12,772
Total$704,569$942,599$1,476,975

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: LEXICON PHARMACEUTICALS, INC. DEF 14A filed March 17, 2023, accession 0001062822-23-000011, and prior-year filings. Open the filing on EDGAR.

How this page was built: the LEXICON PHARMACEUTICALS, INC. filed document, accession 0001062822-23-000011. Every figure is read from that document and cited to the page and table it appears in. Filed March 17, 2023.

$705K
$943K
$1.5M
FY20
FY21
FY22
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU82,670$157,900—
RSU18,243$34,844—
RSU14,173$27,070—
Option2,116—$5.16
Option17,267—$8.38
Option248,010—$3.20
Option23,940—$3.31

Per the Outstanding Equity Awards at Fiscal Year-End table in LEXICON PHARMACEUTICALS, INC.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

LEXICON PHARMACEUTICALS’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Lonnel CoatsChief Executive Officer and Director$4,169,942
Jeffrey WadePresident and Chief Financial Officer$1,990,163
Craig GranowitzSenior Vice President and Chief Medical Officer$1,571,022
Kenneth Kassler-Taub · this pageSenior Vice President, Regulatory and Quality$1,476,975
Brian CrumSenior Vice President and General Counsel$1,450,317

The full LEXICON PHARMACEUTICALS compensation record

free company brief

This page is one person within LEXICON PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the LEXICON PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are LEXICON PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Kenneth Kassler-Taub's compensation dossier · One-time report. No refunds.